[Wardenafil in combined treatment of patients with chronic bacterial prostatitis].
The efficiency of treatment with phosphodiesterase-5 (PDE-5) inhibitors in combination with antibacterial drugs in chronic bacterial prostatitis (CBP) was studied in a randomized trial with participation of 103 CBP patients (mean age 36.2 +/- 8.4 years). Group 1 patients (n = 32) received levofloxacine (500 mg/day) monotherapy for 4 weeks. Group 2 patients (n = 34) received antibacterial treatment plus wardenafil in a dose 10 mg in the evening. Group 3 patients (n = 37) received combined treatment (fluoroquinolone + wardenafil), PDE-5 inhibitor was taken for more than 2 times a week 10-60 min before the coitus. Treatment efficacy was assessed with NIH-CPSI scale, count of bacteria and leukocytes in the pre- and postmassage urine portions, uroflowmetry. By NIH-CPSI scale, a significant (p < 0.001) improvement was seen in dysuria and quality of life in group 2. The control test discovered pyuria in postmassage urine in 7 (21.9%), 4 (11.8%) and 6 (16.2%) patients of group 1, 2 and 3, respectively. Manifest bacteriuria was registered in 3 (9.4%), 2 (5.9%) and 3 (8.1%) patients, respectively. Uroflowmetry reported significant changes (p < 0.05) in urine volume only in patients of group 2. Efficacy of CBP treatment significantly rises in combination of antibacterial treatment with wardenafil.
Aliaev
Iu G
IuG
Vinarov
A Z
AZ
Akhvlediani
N D
ND
D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000652:urine; D004359:Drug Therapy, Combination; D024841:Fluoroquinolones / Q000008:administration & dosage*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000008:administration & dosage*; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage*; D010879:Piperazines / Q000008:administration & dosage*; D011472:Prostatitis / Q000188:drug therapy* / Q000652:urine; D013450:Sulfones / Q000008:administration & dosage; D014227:Triazines / Q000008:administration & dosage; D000069058:Vardenafil Dihydrochloride
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride; D015242:Ofloxacin